


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

5. (currently amended) An arylretinamide for inducing apoptosis in a cancer cell, said arylretinamide having Structure A, B, or C below:



**Structure A**

wherein

R<sub>2</sub> is H, OH, NO<sub>2</sub>, CH<sub>2</sub> OH, a halide, or an alkyl comprising 1-4 carbon atoms,


R<sub>3</sub> is H, OH, NO<sub>2</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, CO<sub>2</sub>H, CH<sub>2</sub>OH, a halide, or an alkyl comprising 1-4 carbon atoms;

R<sub>4</sub> is H, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, NH<sub>2</sub>, NHCOCH<sub>3</sub>, NHCOCH<sub>2</sub>CH<sub>3</sub>, NHCO(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, NHCO(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, NHCOCF<sub>3</sub>, N<sub>3</sub>, NCS, NO<sub>2</sub>, a halide, an alkyl comprising 1-4 carbon atoms, or NHCOCH<sub>2</sub>X, wherein X is a halide;

R<sub>5</sub> is H, NO<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, C((CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, C((CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>)<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, a halide, or an alkyl comprising 1-4 carbon atoms, and


R<sub>6</sub> is H, CO<sub>2</sub>H, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, a halide or an alkyl comprising 1-4 carbon atoms;

provided however that when R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are all H, R<sub>4</sub> is not OH or OCH<sub>2</sub>CH<sub>3</sub>; and also provided that when R<sub>3</sub>, R<sub>5</sub>, and R<sub>6</sub> are all H, and R<sub>2</sub> is OH, R<sub>4</sub> is not CO<sub>2</sub>CH<sub>3</sub>.



**Structure B**

wherein the OH group is at position 2,4, or 5 when the retinamido group is at linked to position 1, and the OH group is at position 3 when the rentinamido group is linked to position 2.




**Structure C**

wherein R<sub>7</sub> is C<sub>1</sub> to C<sub>4</sub> alkyl.

6. (original) The arylretinamide of claim 5 wherein the arylretinamide is a halohydroxyphenyl retinamides which comprises a phenyl moiety that is optionally substituted with an alkyl group .
7. (original) The arylrentiamide of claim 6 wherein the phenyl moiety is substituted with a methyl group.
8. (original) The arylreninamide of claim 6 wherein the halo group is an iodo group.
9. (original) The arylretinamide of claim 5 wherein the arylretinamide is a hydroxy-alkylphenyl retinamides or hydroxy-alkoxyphenyl retinamide, wherein the alkyl groups attached to the phenyl moiety comprise from 1 to 4 carbon atoms.
10. (original) The arylretinamide of claim 9 wherein the arylretinamide is a hydroxy-methylphenyl or hydroxy-methoxyphenyl retinamide.
11. (original) The arylretinamide of claim 5 is a hydroxy-nitrophenyl retinamides or alkylsulfonyl-hydroxy retinamides.

12. (original) The arylretinamide of claim 11 wherein the arylretinamide is an ethylsulfonyl-hydroxy, retinamides.
13. (original) The arylretinamide of claim 5 wherein the arylretinamide is a hydroxy-naphthylphenyl retinamide.
14. (original) The arylretinamide of claim 5 wherein the arylretinamide is an N-alkyl(hydroxyphenyl) retinamides.
15. (original) The arylretinamide of claim 5 wherein the arylretinamide is an aminophenyl retinamides.
16. (original) The arylretinamide of claim 5 wherein the arylretinamide is an alkylhydroxyphenyl retinamides.
17. (original) The arylretinamide of claim 5 wherein the arylretinamide is a carboxy-hydroxyphenyl retinamides selected from the group consisting of *N*-(2'-hydroxy-3'-carboxymethylphenyl)retinamide, *N*-(2'-hydroxy-3'-carboxyphenyl)retinamide, *N*-(2'-hydroxy-6'-carboxymethylphenyl)retinamide, *N*-(2'-hydroxy-6'-carboxyphenyl)retinamide, *N*-(3'-hydroxy-4'-carboxymethylphenyl)retinamide, *N*-(3'-hydroxy-4'-carboxyphenyl)retinamide, *N*-(2'-hydroxy-5'-carboxymethylphenyl)retinamide, *N*-(2'-hydroxy-4'-carboxyphenyl)retinamide, *N*-(4'-hydroxy-3'-carboxymethylphenyl)retinamide, and *N*-(4'-hydroxy-3'-carboxyphenyl)retinamide.
18. (currently amended) An arylretinamide having Structure A below



**Structure A**

wherein

R<sub>2</sub> is H, OH, NO<sub>2</sub>, CH<sub>2</sub> OH, a halide, or an alkyl comprising 1-4 carbon atoms,

R<sub>3</sub> is H, OH, NO<sub>2</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, CO<sub>2</sub>H, CH<sub>2</sub>OH, a halide, or an alkyl comprising 1-4 carbon atoms;

R<sub>4</sub> is H, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, NH<sub>2</sub>, NHCOCH<sub>3</sub>, NHCOCH<sub>2</sub>CH<sub>3</sub>, NHCO(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, NHCO(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, NHCOCF<sub>3</sub>, N<sub>3</sub>, NCS, NO<sub>2</sub>, a halide, an alkyl comprising 1-4 carbon atoms, or NHCOCH<sub>2</sub>X, wherein X is a halide;

R<sub>5</sub> is H, NO<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, C((CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, C((CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>)<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, a halide, or an alkyl comprising 1-4 carbon atoms, and

R<sub>6</sub> is H, CO<sub>2</sub>H, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, a halide, or an alkyl comprising 1-4 carbon atoms;

provided that when R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are all H, R<sub>4</sub> is not OH OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, or O(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>; and also

provided that when R<sub>3</sub>, R<sub>5</sub>, and R<sub>6</sub> are all H, and R<sub>2</sub> is OH, R<sub>4</sub> is not CO<sub>2</sub>CH<sub>3</sub> or CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.

19. (original) A method of inducing apoptosis in a cancer cell comprising contacting the cancer cell with an arylretinamide of claim 1.

20. (original) A method of treating cancer in a subject in need of said treatment, comprising administering one or more arylretinamides of claim 1 to the subject.

21. (original) The method of claim 20 wherein said method further comprises administering calcium glucarate to the subject.